Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Varela

Cardiovascular Disease St George, UT Medical Doctor

NPI 1508220054 CMS profile 5705484

1380 E Medical Center Dr, St George, UT 84790

Open in the dashboard

General payments

$40,449

264 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Varela of St George, UT is reported in the CMS Open Payments database as having received $40,449 across 264 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,079 80
2024 General $9,173 81
2023 General $16,026 65
2022 General $9,840 31
2021 General $296 5
2019 General $35 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Varela
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Daniel Varela were reported at $5,079. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Daniel Varela Cardiovascular Disease median Middle half National median
2019 $35 $450 $127–$1,392 $163
2020 $0 $242 $77–$751 $114
2021 $296 $335 $101–$1,037 $132
2022 $9,840 $395 $121–$1,211 $149
2023 $16,026 $443 $136–$1,283 $160
2024 $9,173 $450 $136–$1,323 $164
2025 $5,079 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $15,861 84 payments
  2. Boston Scientific Corporation $8,168 24 payments
  3. Medtronic, Inc. $5,426 51 payments
  4. Medical Device Business Services, Inc. $3,215 17 payments
  5. Biosense Webster, Inc. $2,727 37 payments
  6. AltaThera Pharmaceuticals LLC $2,031 2 payments
  7. Biotronik Inc. $1,125 22 payments
  8. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $724 8 payments
  9. Cardiva Medical, Inc. $395 8 payments
  10. Astellas Pharma US Inc $198 2 payments
  11. Other $579 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $13,898 4 payments
  2. Food and Beverage $13,010 212 payments
  3. Travel and Lodging $10,261 38 payments
  4. Consulting Fee $1,875 1 payment
  5. Education $1,405 9 payments
Products named General payments · program years 2019–2025
  1. Carto 3 $5,538 47 payments
  2. EMBLEM MRI S-ICD $5,000 1 payment
  3. ENSITE PRECISION $3,968 34 payments
  4. General - Therapies $2,263 9 payments
  5. Sotalol Hydrochloride $2,031 2 payments
  6. Micra $2,022 26 payments
  7. AVEIR $1,365 11 payments
  8. AURORA EV-ICD MRI SURESCAN $1,134 17 payments
  9. ASSURITY $794 3 payments
  10. LifeVest $724 8 payments
  11. Other $5,932 104 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$33,331

Medicare's payments for the services billed

Medicare patients

148

Average age 77

Services billed

274

66 women, 82 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 60%
Ischemic heart disease 47%
Arthritis 39%
Heart failure 34%
Chronic kidney disease 28%
Diabetes 24%
Depression 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Sotalol Hydrochloride
  • AltaThera Pharmaceuticals LLC $2,031
$2,031 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

264 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record